Your Mounjaro first dose had no effect — here's what that means

You injected, put the pen back in the fridge, and felt… nothing

That is probably the most common experience at 2.5mg, and it catches a lot of people off guard. The plain white DPD box arrives, you unpack the KwikPen, follow the injection steps, and then wait. No dramatic drop in hunger. No clear signal that anything has changed. It can feel as though the medicine is not working, or that you were sent the wrong thing.

What is actually happening is more mundane and more deliberate. Tirzepatide's dual mechanism (stimulating both GIP and GLP-1 receptors to slow gastric emptying and signal fullness to the brain) takes time to exert a meaningful effect, and the 2.5mg dose is calibrated well below the range where that effect becomes clinically significant for most people. The opening four weeks are essentially a settling-in period. Your body is meeting the medicine for the first time. The prescriber's aim is to get you through that period without the nausea and vomiting that a higher starting dose would cause in a larger proportion of patients.

The what to expect from your first Mounjaro dose guide covers the early days in more detail, including what sensations (however subtle) some people do notice at 2.5mg. The short answer, though: feeling nothing is not a failure. It is the plan.

When the effect is supposed to arrive, and what the trial data actually shows

The SURMOUNT-1 trial, which ran for 72 weeks, reported an average body-weight reduction of around 20–21% at the 15mg maintenance dose. That figure is the one most cited in headlines about Mounjaro. What rarely makes the headline is that participants spent the first eight weeks at 2.5mg and 5mg combined, the dose range where the effect is minimal by design. The meaningful weight-loss trajectory emerged as doses increased, and it built gradually over months, not the first few injections. You can read the full Mounjaro overview for more context on how those trial outcomes translate to real-world treatment.

For most people, appetite suppression becomes perceptible somewhere around the 5mg or 7.5mg stage. Some notice a slight reduction in evening snacking earlier; others feel very little until a higher dose. Both responses sit within the normal range. The 5mg dose page sets out what typically shifts at that point in the schedule.

The prescriber overseeing your treatment (a named clinician, not an automated system) will review your progress before any dose change. That review is where concerns about lack of effect belong: in a clinical conversation, not a self-directed dose increase. According to NHS guidance on tirzepatide, dose adjustments are determined by clinical assessment of tolerability and response.

What 'no effect' might actually mean, and the one thing worth checking

There is a difference between the medicine producing no weight-loss effect yet (expected) and the medicine genuinely not reaching your system (rare, but worth ruling out). A few practical things can reduce how much tirzepatide your body absorbs: injecting into a site with significant scar tissue, not rotating injection sites, or injecting too shallowly into skin rather than into the subcutaneous fat underneath. The guide to taking your first Mounjaro dose correctly covers technique, storage, and site rotation, worth a quick read if you have any doubt about whether your injection went as intended.

Storage matters too. Mounjaro must be kept refrigerated at 2–8°C until you are ready to use it. A pen left at room temperature beyond the window set out in the Patient Information Leaflet may lose potency. If there is any chance yours was stored incorrectly, the spare-dose guidance and your prescriber can advise on next steps.

Side effects at the 2.5mg stage are usually mild if they appear at all. If you are curious what is considered typical (including the GI symptoms that some people do notice) the 2.5mg side effects page sets that out clearly. The absence of side effects does not mean the pen failed; it often just means the dose is doing its job of gradual introduction quietly.

What happens next, and when to raise it with your prescriber

The standard titration schedule moves in four-week steps, guided by your prescriber's clinical assessment of how you are tolerating each dose. Feeling no effect at 2.5mg is not a clinical reason to skip ahead; pushing the dose too fast is what causes the nausea, vomiting and dizziness that lead people to stop treatment altogether. Patience here is not passive, it is what makes the higher, effective doses reachable.

If you are at 5mg or above and still noticing nothing at all, that is a different conversation, and the right place to have it is with the prescriber who reviewed your case, not by adjusting your own dose. A look at what tirzepatide's first dose phase involves clinically may help frame that conversation. Cost questions occasionally come up alongside efficacy ones, if you want to understand the broader picture of treatment pricing in the UK, the context around Mounjaro's UK pricing is useful background.

Tirzepatide is licensed in the UK for weight management alongside a reduced-calorie diet and increased physical activity, for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. As with any prescription medicine, eligibility is determined by a clinical assessment, BMI alone is not a guarantee. If you have questions about your treatment, our support team is available seven days a week, or you can speak to our prescribers through a new free consultation.